Study Of Exenatide Treatment Showed Improved Beta-Cell Function

Armen Hareyan's picture

Study Of Exenatide Treatment

Amylin Pharmaceuticals, Eli Lilly and Company announced study results comparing treatment of exenatide injection with insulin glargine on beta-cell function, glycemic control and weight in people with type 2 diabetes.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.